Patents Assigned to Orphelia Pharma
  • Oral suspension of temozolomide
    Patent number: 11730732
    Abstract: A pharmaceutical liquid suspension comprising: temozolomide or a salt thereof; at least one agent controlling the solid state of temozolomide in suspension; a pharmaceutically acceptable liquid vehicle; and optionally at least one acid in a quantity so that the pH of the composition is below 5; or a powder blend for reconstituting said suspension, is provided.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: August 22, 2023
    Assignees: Orphelia Pharma, Institut Gustave Roussy
    Inventors: Maxime Annereau, Jérémy Bastid, Hugues Bienayme, François Lemare, Mathieu Schmitt, Lionel Tortolano, Samuel Abbou
  • Solid dosage forms of vigabatrin
    Patent number: 10813898
    Abstract: The invention pertains to a solid dosage form comprising vigabatrin; a superdisintegrant, advantageously chosen from the list consisting of crospovidone, a cellulose derivative and a starch derivative; a non-reducing sugar, advantageously chosen from the list consisting of mannitol, xylitol, and sorbitol; and a stearate derivative, advantageously a stearate or stearyl fumarate salt, more advantageously sodium stearyl fumarate or magnesium stearate.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: October 27, 2020
    Assignee: Orphelia Pharma
    Inventors: Charles Uzarama, Patrick Gosselin, Marie-Pierre Flament
  • ORAL SUSPENSION OF TEMOZOLOMIDE
    Publication number: 20200188390
    Abstract: The present invention concerns a pharmaceutical composition, advantageously a liquid suspension, comprising: a. temozolomide or a salt thereof; b. at least one agent controlling the solid state of temozolomide in suspension; c. a pharmaceutically acceptable liquid vehicle, advantageously water; d. optionally at least one acid in a quantity so that the pH of the composition is below 5; or a powder blend for reconstituting said suspension.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 18, 2020
    Applicants: Orphelia Pharma, Institut Gustave Roussy
    Inventors: Maxime ANNEREAU, Jérémy BASTID, Hugues BIENAYME, François LEMARE, Mathieu SCHMITT, Lionel TORTOLANO